Hereditary Ataxia Research on Multi-Omics and Neuroclinical Insights in the Yangtze Delta

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

5000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-06-01

Study Completion Date

2035-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this observational study is to explore the clinical and genetic characteristics, multi-omics profiles, disease mechanisms, biomarkers, and potential therapeutic targets of hereditary ataxia (HA) in patients diagnosed with HA, primarily in the Yangtze River Delta region of China. The main questions it aims to answer are:

* What are the key pathogenic genetic variants, modifying factors and special inheritance patterns underlying HA?
* How do multi-omics profiles correlate with clinical phenotypes, disease progress and mechanism in HA patients?
* What are the implications of these findings for clinical practice?

Participants will:

* Undergo retrospective and prospective clinical data collection through long-term follow-up to observe disease onset, progression, and outcomes.
* Provide biological samples (e.g., blood, skin) to establish a biobank for multi-omics analyses.
* Be characterized using multidimensional omics technologies to identify disease-related molecular signatures, progression mechanisms, and potential regulatory targets.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Neuroimaging Changes in Hereditary Ataxia

NCT05160883

Hereditary Ataxia

RECRUITING

Phenotypic and Genotypic Studies in Congenital and Early Onset Ataxias

NCT01488461

Congenital Cerebellar Ataxias Early-onset Cerebellar Ataxias

COMPLETED

A Registered Cohort Study on Cerebellar Ataxia in the Organization in South-East China for Cerebellar Ataxia Research (OSCCAR)

NCT04010214

Cerebellar Ataxia

RECRUITING

Biomarker Research in Inherited Movement Disorders

NCT05034172

Inherited Movement Disorders Spinocerebellar Ataxias Hyperkinetic Disorders

RECRUITING

Phenotypes, Biomarkers and Pathophysiology in Hereditary Spastic Paraplegias and Related Disorders

NCT03981276

Hereditary Spastic Paraplegia

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This project aims to establish a representative and continuously expanding cohort of hereditary ataxia in the Yangtze River Delta region of China. By integrating both retrospective and prospective study designs, the investigators will implement a observational ambispective cohort approach to comprehensively capture the natural history of the disease - including its onset, progression, and clinical outcomes - through systematic data collection from historical records and long-term follow-up of enrolled cases. In parallel, a biobank will be established by collecting biospecimens such as blood and skin samples from participants, providing high-quality biological materials for future research. Utilizing multi-omics technologies, including genomics, transcriptomics, epigenomics, etc., the investigators will explore key pathogenic genetic variants, disease-modifying factors, mechanisms underlying disease progression, biomarkers, and potential therapeutic targets. Through this integrated approach, the project is expected to significantly advance basic and translational research on hereditary ataxia, ultimately contributing to the development of precision diagnosis and effective intervention strategies for these debilitating neurodegenerative disorders.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hereditary Ataxia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

OTHER

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

HA Cohort

Patients with clinical suspected or genetic-confirmed hereditary ataxia

None of intervention

Intervention Type OTHER

No specific intervention was implemented in this study.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

None of intervention

No specific intervention was implemented in this study.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Presence of progressive ataxia as a primary or persistent clinical feature;
* Sufficient evidence to exclude acquired causes of ataxia (e.g., chronic intoxication, immune-mediated inflammation, acquired vitamin deficiency, acute injury, stroke, infection, or space-occupying disorders);
* For sporadic late-onset cases (≥30 years), disease duration must exceed 3 years, with no prominent progressive autonomic dysfunction or other features indicative of multiple system atrophy-cerebellar type (MSA-C);
* Ability and willingness of the participant or legal guardian to provide informed consent and complete the entire study process.

Exclusion Criteria

* Patients whose causative genes identified through genetic testing and analysis do not fall within the defined spectrum of hereditary ataxias, based on consensus classifications from the MDS Task Force on Genetic Movement Disorders and the SRCA Working Group, along with current research advancements;
* Presence of concurrent cerebrovascular disease, brain tumors, or severe systemic illness;
* Refusal to sign informed consent or provide biological samples by the participant or legal representative;
* Inability or unwillingness to participate in follow-up assessments.

Eligible Sex

ALL

Accepts Healthy Volunteers

No